IL293107A - Adenosine receptor antagonist compounds - Google Patents

Adenosine receptor antagonist compounds

Info

Publication number
IL293107A
IL293107A IL293107A IL29310722A IL293107A IL 293107 A IL293107 A IL 293107A IL 293107 A IL293107 A IL 293107A IL 29310722 A IL29310722 A IL 29310722A IL 293107 A IL293107 A IL 293107A
Authority
IL
Israel
Prior art keywords
substituted
compound
amino
alkyl
cancer
Prior art date
Application number
IL293107A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ildong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ildong Pharmaceutical Co Ltd filed Critical Ildong Pharmaceutical Co Ltd
Publication of IL293107A publication Critical patent/IL293107A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
IL293107A 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds IL293107A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020190149117A KR20210061202A (ko) 2019-11-19 2019-11-19 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도
PCT/IB2020/000971 WO2021099838A1 (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Publications (1)

Publication Number Publication Date
IL293107A true IL293107A (en) 2022-07-01

Family

ID=75980093

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293107A IL293107A (en) 2019-11-19 2020-11-19 Adenosine receptor antagonist compounds

Country Status (14)

Country Link
US (1) US12606564B2 (https=)
EP (1) EP4061817A4 (https=)
JP (2) JP7681616B2 (https=)
KR (3) KR20210061202A (https=)
CN (2) CN116425756B (https=)
AU (2) AU2020386189B2 (https=)
BR (2) BR122023020015A2 (https=)
CA (1) CA3158731A1 (https=)
CL (1) CL2022001307A1 (https=)
IL (1) IL293107A (https=)
MX (1) MX2022005976A (https=)
PH (1) PH12022551223A1 (https=)
TW (3) TWI851336B (https=)
WO (3) WO2021099832A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806350B2 (en) 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders
CN119173276A (zh) 2022-04-13 2024-12-20 吉利德科学公司 用于治疗表达Trop-2的癌症的组合疗法
TW202508599A (zh) * 2023-05-19 2025-03-01 南韓商尹諾衛醫藥有限公司 用於神經保護或治療α突觸核蛋白及/或神經發炎相關疾病的化合物
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
KR20250123663A (ko) 2024-02-08 2025-08-18 아이리드비엠에스 주식회사 Cxcr7 수용체 조절제 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA971896B (en) * 1996-03-26 1998-09-07 Du Pont Merck Pharma Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives
EP0901476A4 (en) * 1996-03-26 2001-08-16 Du Pont Pharm Co PYRIDINES AND PYRIMIDINES FUSION ARYLOXY AND ARYLTHIO AND DERIVATIVES THEREOF
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
DK1444233T3 (da) 2001-11-09 2011-10-17 Gilead Palo Alto Inc A2B-adenosinreceptorantagonister
EP1615926A1 (en) * 2003-04-21 2006-01-18 Ustav Organicke Chemie A Biochemie Akademie Ved Ceske Republiky (purin-6-yl) amino acid and production method thereof
WO2008153947A2 (en) * 2007-06-07 2008-12-18 Amgen Inc. Heterocyclic compounds as raf kinase modulators
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
GB0906579D0 (en) * 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011050160A1 (en) 2009-10-22 2011-04-28 Biogen Idec Ma Inc. Pharmaceuticals, compositions and methods of making and using the same
EA201890730A1 (ru) 2015-09-16 2018-10-31 Локсо Онколоджи, Инк. Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
DE102017125533A1 (de) 2017-10-31 2019-05-02 Helmholtz-Zentrum Dresden - Rossendorf E.V. 4-(Furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-6-amin-Derivate und deren Verwendung
BR122023024273A2 (pt) 2018-02-27 2024-02-20 Incyte Corporation Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos
EP4061798B1 (en) 2019-11-19 2025-03-12 Clariant International Ltd Solvates of abscisic acid and liquid compositions containing abscisic acid
MX2022005914A (es) 2019-11-19 2022-08-04 Modag Gmbh Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Also Published As

Publication number Publication date
EP4061817A4 (en) 2023-11-01
TW202342481A (zh) 2023-11-01
KR20240148969A (ko) 2024-10-11
TWI851336B (zh) 2024-08-01
CN114829363B (zh) 2024-10-01
KR102752564B1 (ko) 2025-01-14
EP4061817A1 (en) 2022-09-28
WO2021099838A1 (en) 2021-05-27
WO2021099832A2 (en) 2021-05-27
KR102749480B1 (ko) 2025-01-07
CA3158731A1 (en) 2021-05-27
JP2023505915A (ja) 2023-02-13
MX2022005976A (es) 2022-08-18
TW202132304A (zh) 2021-09-01
CN114829363A (zh) 2022-07-29
AU2023202886A1 (en) 2023-05-25
WO2021099832A3 (en) 2021-07-01
CN116425756B (zh) 2025-05-13
BR122023020015A2 (pt) 2024-02-27
PH12022551223A1 (en) 2023-07-17
WO2021099838A9 (en) 2021-09-30
AU2020386189A1 (en) 2022-06-02
WO2021099838A8 (en) 2021-08-12
CL2022001307A1 (es) 2023-03-03
KR20220104760A (ko) 2022-07-26
WO2021099837A1 (en) 2021-05-27
TWI850492B (zh) 2024-08-01
TW202132305A (zh) 2021-09-01
CN116425756A (zh) 2023-07-14
US20230159534A1 (en) 2023-05-25
JP7681616B2 (ja) 2025-05-22
JP2025120182A (ja) 2025-08-15
US12606564B2 (en) 2026-04-21
AU2020386189B2 (en) 2024-05-16
KR20210061202A (ko) 2021-05-27
BR112022009487A2 (pt) 2023-02-23
AU2023202886B2 (en) 2024-11-14

Similar Documents

Publication Publication Date Title
JP7672451B2 (ja) Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
KR101974793B1 (ko) Cot 조정제 및 그의 사용 방법
US12606564B2 (en) Adenosine receptor antagonist compounds
AU2014400628A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
JP7777596B2 (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
EP4590397A1 (en) Pcsk9 inhibitors and methods of use thereof
JP2025515285A (ja) 大環状複素環及びその使用
CN109721600B (zh) 一类含氮稠环化合物及其制备方法和用途
JP7789567B2 (ja) ピラゾロン縮合ピリミジン化合物、その製造方法及び使用
CN109476670B (zh) 二环杂芳基衍生物
CN111763217B (zh) 一类噻吩并氮杂环类化合物、制备方法和用途
EA051725B1 (ru) Соединения-антагонисты аденозиновых рецепторов
EA050210B1 (ru) Соединения-антагонисты аденозиновых рецепторов
HK40077081A (en) Adenosine receptor antagonist compounds
HK40097385A (zh) 腺苷受体拮抗剂化合物及其应用